Animal Health Research Reviews

Review Article

Alphavirus replicon vaccines

Ryan L. Vander Veena1a2a3 c1, D. L. Hank Harrisa1a4a5 and Kurt I. Kamruda1a4

a1 Harrisvaccines Inc., Ames, IA 50010, USA

a2 Immunobiology Program, Iowa State University, Ames, IA 50011, USA

a3 Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA

a4 Department of Animal Science, College of Agriculture, Iowa State University, Ames, IA 50011, USA

a5 Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Ames, IA, 50011, USA

Abstract

The alphavirus replicon technology has been utilized for many years to develop vaccines for both veterinary and human applications. Many developments have been made to the replicon platform recently, resulting in improved safety and efficacy of replicon particle (RP) vaccines. This review provides a broad overview of the replicon technology and safety features of the system and discusses the current literature on RP and replicon-based vaccines.

(Received November 23 2011)

(Accepted January 26 2012)

(Online publication March 21 2012)

Correspondence:

c1 Corresponding author: E-mail: rvanderveen@harrisvaccines.com

0Comments